This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Risk and prognosis of endometrial cancer with tamoxifen

Authoring team

Tamoxifen (TAM) is used as antihormonal treatment for postmenopausal breast cancer patients with positive estrogen receptors

  • one of the most significant and deleterious side effects of postmenopausal TAM treatment appears to be its proliferative effect on the endometrium
  • overall endometrial pathologies, including hyperplasia, polyps, carcinoma and sarcoma have been identified in up to 36.0% of postmenopausal breast cancer TAM-treated patients

Endometrial hyperplasia

  • is more commonly diagnosed in TAM-treated patients as compared to nontreated patients, and among postmenopausal breast cancer TAM-treated patients with vaginal bleeding as compared to patients without this symptom
  • endometrial hyperplasia has been reported to occur in 4-30% of TAM-treated patients (4)
    • studies suggest a higher rate of endometrial hyperplasia among tamoxifen-treated patients with symptoms of vaginal bleeding

Endometrial polyps

  • represent the most common endometrial pathology associated with postmenopausal TAM exposure, with a rate of 8-36.0%
  • some risk factors have been identified for endometrial polyps in postmenopausal breast cancer TAM-treated patients:
    • older age at menopause
    • longer duration of breast disease
    • heavier body weight
    • thicker endometrial thickness, measured by transvaginal ultrasonography, compared with similar patients without endometrial polyps

Malignant endometrial polyps

  • a high rate of malignant transformation with a high grade of malignancy was reported in endometrial polyps recovered from postmenopausal breast cancer TAM-treated patients - malignant transformation was reported in 3.0-10.7% of endometrial polyps recovered
  • vaginal bleeding was associated with only 50.0% of the cases
  • no correlation between malignant polyps and polyp size or treatment duration

Endometrial cancer

  • risk does not decrease after cessation of TAM treatment, as the effect of TAM can last several years beyond discontinuation of exposure
  • an increased rate of endometrial cancer was also reported in healthy postmenopausal TAM-treated women with a high risk for breast cancer, predominantly in women aged 50 years or older, who participated in a randomized, double-blind, TAM chemoprevention trial, compared to similar, healthy, nontreated women (RR = 2.53; 95% CI = 1.35-4.97)
  • longer duration of TAM use was associated with an increased risk of endometrial cancer, when compared to nontreated patients
  • only 2-3/1000 per year are estimated to develop symptomatic endometrial cancer
  • prognosis
    • long-term TAM users are more likely to succumb to endometrial cancer than nonusers, due to the unfavorable histology of the endometrial malignancy and an advanced stage at diagnosis
    • endometrial cancer mortality rate among TAM-treated patients was significantly higher compared to nontreated patients (33.3% vs. 2.6%; P = 0.005)
    • 3 year survival was worse with increasing exposure to TAM (3):
      • 76% for 5 years or more of tamoxifen
      • 85% for 2-5 years
      • 94% for non-users
    • 5-year overall endometrial cancer survival rate was significantly worse for TAM users compared with nonusers (40% vs. 64%; P = 0.01)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.